Table 2.
Results of the Cox regression analysis for predicting the overall survival.
| Variable | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | |
| Age | ||||||
| <65 vs. ≥65 | 1.25 | 0.80–1.95 | 0.322 | 1.22 | 0.72–2.08 | 0.461 |
| Sex | ||||||
| male vs. female | 1.19 | 0.75–1.89 | 0.467 | 0.68 | 0.38–1.20 | 0.182 |
| Liver metastasis | ||||||
| no vs. yes | 0.76 | 0.44–1.31 | 0.318 | 0.77 | 0.41–1.47 | 0.773 |
| Peritoneum metastasis | ||||||
| no vs. yes | 0.86 | 0.49–1.49 | 0.58 | 0.69 | 0.36–1.34 | 0.27 |
| Lung metastasis | ||||||
| no vs. yes | 1.03 | 0.66–1.62 | 0.884 | 0.93 | 0.53–1.61 | 0.783 |
| RAS status | ||||||
| M+ vs. WT | 1.06 | 0.68–1.66 | 0.782 | 0.99 | 0.61–1.60 | 0.969 |
| Primary tumor location | ||||||
| left colon vs. right colon | 0.93 | 0.56–1.53 | 0.768 | 0.95 | 0.53–1.71 | 0.874 |
| Grade | ||||||
| low vs. high | 0.58 | 0.34–0.99 | 0.048 | 0.6 | 0.33–1.11 | 0.104 |
| PS (ECOG) | ||||||
| 0 vs. 1 | 0.64 | 0.41–1.007 | 0.053 | 0.65 | 0.38–1.10 | 0.107 |
| CEA | ||||||
| ≤2 ULN vs. >2 ULN | 0.53 | 0.33–0.84 | 0.007 | 0.58 | 0.34–0.98 | 0.041 |
| miR-618 | ||||||
| high/intermediate vs. low expression | 0.56 | 0.36–0.89 | 0.013 | 0.51 | 0.30–0.86 | 0.012 |
M+—positive for RAS mutations; WT—wild type; PS (ECOG)—performance status (Eastern Cooperative Oncology Group); ULN—upper limit of normal; CEA—Carcinoembryonic antigen.